Scope and claim breadth of US Patent 9,416,112: what chemical space does it actually cover, and where are the likely patent “blocking” edges?
US 9,416,112 claims a broad genus of substituted aromatic compounds (and pharmaceutically acceptable salts) defined by multiple substitution-variable frameworks. Claim 1 is written as a highly parameterized structure where the patentable subject matter is the selection and pairing of two distinct aryl substitution patterns (R2 and R4) with an allowed range of substituents (R8) and constrained backbone halogen/hydrogen settings (R5, R6). Dependent claims then carve narrower embodiments by specifying substitution counts (di-, tri-), substitution positions (ortho/meta/para for R4), and halogen identity (fluoro/chloro).
Because the claims are “formula plus variable ranges,” enforceable scope will track two key constraints in Claim 1: (i) R2 and R4 must be different rings with defined substitution patterns, and (ii) the R2 ring is explicitly prohibited from being 3,4,5-trimethoxyphenyl. Everything else is left open to wide combinatorial selection via Ra/Rb/Rc/Rd and the methylene spacer length m (1 to 3). Claim 9 adds formulation coverage (composition with a pharmaceutically acceptable carrier), while Claims 10-20 select specific salt and halogen embodiments.
What compounds are covered by US 9,416,112 claim 1 (genus scope)
Claim 1 scope in one line: a compound of a defined general structure where two different aromatic substituent regimes (R2 and R4) are populated with substituents R8 from an enumerated scaffold set, with specific exclusions and fixed choices for R5 and R6.
1) Core scaffold variables that define the chemical boundary
Claim 1 does not read as a single “named molecule.” It reads as a constrained genus. The patentable boundaries are defined by these elements:
- R2: a phenyl ring with either:
- mono-substitution at the 3- or 5-position with an R8 group, or
- di- or tri-substitution where the R8 groups can be the same or different.
- Express exclusion: R2 is not 3,4,5-trimethoxyphenyl.
- R4: a phenyl ring substituted with one or more R8 groups.
- R2 and R4 must be different: the claim requires R2 ≠ R4 (not merely “not identical substituents,” but “R2 and R4 are different” in the claim language).
- R5: halogen (no identity in Claim 1).
- R6: hydrogen (fixed).
- R8: substituent chosen from a defined set of functionalized groups (Ra/Rb-containing units; multiple protected versions of ether and amide-like fragments appear in the R8 list).
- m: integer 1 to 3, controlling a methylene spacer length in multiple R8 definitions.
- Ra/Rb/Rc/Rd: additional variable groups defining how bulky/polar/functional the R8 substituents can be.
2) R8 is the main expansion engine
Claim 1’s breadth is driven by the fact that each R8 can be any member of a relatively large enumerated substituent set. Those substituents share repeated patterns using:
- Ra: selected from multiple hydrophobic/alkyl/aryl/cycloalkyl/heterocycle/arylalkyl-like choices.
- Rb: selected from a different set that includes heteroatom substituents and strong electron-withdrawing groups such as CF3 and multiple sulfonyl/sulfoxide-like and carbonyloxy/aminocarbonyl patterns.
- Rc and Rd: each independently hydrogen or Ra, so many R8 variants can carry hydrogen or another Ra group.
- m: 1 to 3 methylene units in several of the R8 options, enabling short-linker analogs.
The net effect: even if the core heteroatom connectivity is fixed by the general formula, the side chain “endpoint chemistry” is highly variable. This makes design-around by modifying R8 endpoints harder, because many endpoints are already included through Ra/Rb/Rc/Rd enumerations.
What limits are built into claim 1 (hard constraints that narrow enforceable scope)
The claim has three explicit hard constraints:
- R2 positional/substitution constraint
- If R2 is mono-substituted, it must be at 3- or 5-position.
- If R2 is di/tri-substituted, it can involve 2- or 3- R8 groups with flexible choice of each R8 member.
- R2 exclusion
- R2 cannot be 3,4,5-trimethoxyphenyl.
- R2 and R4 must be different
- Even if both rings are phenyl and both are “substituted with R8 groups,” the claim requires that the two rings represent different defined patterns (not the same defined R-substitution regime).
The rest is mostly “select any from list” rather than “tight functional limitations,” which generally increases scope.
How do dependent claims narrow or target specific embodiments?
Dependent claims 2-20 carve out subsets that are useful for claim charting, because they define more specific features that may be easier to map in an accused product or competitor series.
Substitution-pattern dependent claims
- Claim 2: R2 is a phenyl di-substituted pattern (R8 groups same or different).
- Claim 3: R2 is 3,4-disubstituted.
- Claim 13: R2 is phenyl tri-substituted.
- Claim 3 vs Claim 2: Claim 3 is a positional subset inside the broader di-substitution regime.
R4 substitution pattern and position dependent claims
- Claim 4: R4 is mono-substituted with an R8 group.
- Claims 5-7: R4 mono-substituted at:
- ortho (Claim 5)
- meta (Claim 6)
- para (Claim 7)
- Claims 14-18: mirror Claim 4-7 but in the tri-substituted R2 context:
- Claim 14: R4 mono-substituted with R8
- Claims 16-18: R4 ortho/meta/para (with some duplication artifacts in text: Claim 14 appears twice; the provided text repeats Claim 14 and then continues with position-specific claims. Enforceability in practice will follow the printed patent text.)
Practical impact: position-specific claims are useful for distinguishing competitor molecules where R2 substitution is similar but R4 orientation differs.
Halogen identity dependent claims
- Claim 8: R5 is fluoro.
- Claim 11-12: Claims in the same neighborhood for different precursor claim numbers:
- Claim 11: R5 is fluoro (in a dependency chain tied to Claim 5)
- Claim 12: R5 is chloro (also tied to Claim 5)
- Claims 19-20: similar halogen specificity in the Claim 15 chain:
- Claim 19: R5 is fluoro
- Claim 20: R5 is chloro
Practical impact: if a competitor chooses Br or I or other halogens for R5, the dependent claims may not read, but Claim 1 still covers “halogen” generically.
Formulation and salt coverage
- Claim 9: pharmaceutical composition comprising compound of Claim 1 and pharmaceutically acceptable carrier/diluent/excipient.
- Claim 10: composition where compound is a pharmaceutically acceptable salt.
Practical impact: even if a generic applicant argues a different salt form, Claim 10 is explicitly tied to “pharmaceutically acceptable salt” of the Claim 1 compound, so the salt strategy must avoid having the “same compound” as claimed.
How strong is the patent estate likely to be on chemical structure coverage (based on claim architecture)
Claim 1 is broad at the genus level because it includes:
- multiple R2 substitution states (mono at 3/5; di; tri),
- R4 phenyl with one or more R8 substituents,
- a large enumerated set of substituents for each R8 via Ra/Rb options,
- spacer-length freedom m = 1–3,
- and a generic “halogen” setting for R5.
The most meaningful narrowing features are:
- R2 must meet the specified positional/substitution rules and cannot be 3,4,5-trimethoxyphenyl.
- R2 and R4 must be different.
- R6 is fixed to hydrogen.
Design-around realities:
A competitor can potentially avoid the patent by altering at least one of:
- the allowed R2 substitution geometry (e.g., move the only mono substituent off 3 or 5),
- the R2 exclusion case (must not be the banned trimethoxy pattern),
- the “R2 and R4 are different” requirement (requires matching the claim’s definition of “different”),
- the R6 requirement (change R6 from hydrogen), or
- the R8 enumerated substituent set (introduce R8 groups not falling within the explicit Ra/Rb-defined list, not merely “similar” groups).
Because R8 is enumerated rather than “general substituted,” an “invent-around” often targets the substituent identity: substituting a functional group that does not fit any of the R8 subformulas as written.
Patent landscape analysis constraints
No publication number besides US 9,416,112 is provided, and no bibliographic data (assignee, filing date, priority date, related patents, continuation status, prosecution history, or specification-defined preferred compounds) is included. Without those elements, a complete US landscape map (family size, related continuations/divisionals, co-owned/implied claim coverage, and cross-litigation) cannot be constructed while maintaining accuracy.
Accordingly, the analysis below stays at the claim-scope and boundary level represented in the text of Claims 1-20 provided.
US 9,416,112 claim-scope “coverage grid” (how to map accused products quickly)
Use this grid as a claim-chart checklist.
| Claim element |
What you check in an accused compound |
Coverage effect |
| Compound structure with R2/R4 framework |
Identify the two phenyl rings in the accused structure and how each is substituted |
Determines whether base genus applies |
| R2 mono-substitution position |
If R2 has only one R8, confirm it is at 3 or 5 |
Excludes 2,4,6 positions for mono-R2 embodiments |
| R2 di/tri substitution pattern |
Confirm R2 has 2 or 3 R8 substituents as needed |
Locks into Claims 2/13 subsets |
| R2 exclusion |
Confirm R2 is not exactly 3,4,5-trimethoxyphenyl |
Single explicit carve-out |
| R4 substitution count and orientation |
Confirm whether R4 has one or more R8; for mono claims check ortho/meta/para |
Drives dependent-claim hit/miss |
| R2 and R4 “are different” |
Compare the claim-defined identity of R2 and R4 regimes |
A likely litigation focal point |
| R5 halogen |
Identify the halogen on the backbone location |
Claim 1 covers any halogen; dependent claims require F or Cl |
| R6 hydrogen |
Confirm R6 is hydrogen (no substitution) |
Hard bar if altered |
| Each R8 ∈ enumerated set |
Map each R8 group to one of the listed R8 formulas using Ra/Rb/Rc/Rd and m |
Primary “design-around” lever |
| Each Ra ∈ list |
Check Ra is within allowed alkyl/cycloalkyl/arylalkyl/heterocycles list |
Filters acceptable endpoints |
| Each Rb ∈ list |
Check Rb is within allowed ORd/haloalkyloxy/CF3/sulfonyl/sulfoximide/OC(O)/etc list |
Another endpoint filter |
| m = 1 to 3 |
Check linker length |
Out-of-range analogs avoid many R8 members |
| Claim 9 composition |
Does the product sell as formulation containing the claimed compound? |
Adds formulation coverage |
| Claim 10 salt |
Is it a pharmaceutically acceptable salt of the compound? |
Salt strategy must avoid “salt of claimed compound” |
Key takeaways
- US 9,416,112 Claim 1 is a broad genus claim driven by enumerated R8 substituents with variable endpoints (Ra/Rb/Rc/Rd) and a short linker-length parameter (m = 1–3).
- The claim’s enforceable “hard stops” are R2 positional/substitution constraints, the explicit prohibition on R2 = 3,4,5-trimethoxyphenyl, the requirement that R2 and R4 are different, and R6 = hydrogen.
- Dependent claims add litigation-friendly specificity for R2 di/tri substitution, R4 mono substitution and ortho/meta/para orientation, and R5 = fluoro or chloro.
- Formulation coverage exists (Claims 9-10) for compositions and pharmaceutically acceptable salts of the Claim 1 compounds.
